Theralase Technologies (TLT) investor relations material

Executive summary

• Transitioned from preclinical research to clinical development and commercialization, focusing on bladder cancer and expanding into multiple oncology and virology indications.

• Achieved a key milestone by completing enrollment in phase II bladder cancer clinical study, exceeding target with 91 patients enrolled.

• Signed a collaborative clinical development agreement with Ferring Pharmaceuticals to expand the Phase II NMIBC clinical program.

• Gross margin improved to 62% of revenue, up from 54% in 2024, despite lower sales.

• Research and development expenses decreased by 9%, reflecting reduced costs in clinical study enrollment and treatment.

Financial highlights

• Total revenue for 2025 was $816,468 (CAD 816,000), a 21% decrease year-over-year, all from Cool Laser Therapy systems.

• Canadian revenue decreased 15% to CAD 764,000; U.S. revenue dropped 60% to CAD 47,000; international sales fell 71% to CAD 6,000.

• Cost of sales decreased to $309,337 (38% of revenue), improving gross margin to 62%.

• Net loss was $4,120,817 (CAD 4.1 million), including $840,000 in non-cash expenses; Drug Division accounted for 83% of the loss.

• Operating expenses: selling $287,012 (down 19-20%), admin $1,943,014 (up 12%), R&D $2,308,163 (down 9-11%).

Outlook and guidance

• Plans to file New Drug Application with Health Canada and FDA in Q3 2026; marketing approval expected H1 2027.

• Actively pursuing commercialization and strategic partnerships for Ruvidar® globally.

• GLP toxicology studies for new indications expected to complete in Q3 2026, with adaptive phase 0/I/II clinical studies to follow.

• Anticipates becoming a fully operational, self-sustained pharmaceutical company in 2027.